Why Is Wegovy So Expensive? The 7 Factors Behind the $1,349 Monthly Price Tag

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy's $1,349 monthly list price reflects patent-protected manufacturing, 8-year clinical trial costs exceeding $2 billion, specialty cold-chain distribution, and Novo Nordisk's pricing strategy in a market with limited competition
• Manufacturing costs for GLP-1 receptor agonists run approximately $80-120 per monthly dose, meaning the markup covers R&D recovery, distribution infrastructure, and profit margins
• The FDA shortage designation allowing compounded semaglutide has created a parallel market where the same active ingredient costs $179-299 monthly through telehealth platforms
• Insurance coverage varies dramatically: 23% of commercial plans cover Wegovy for obesity as of 2026, while Medicare explicitly excludes weight-loss medications by statute

Direct answer (40-60 words)

Wegovy costs $1,349 per month because Novo Nordisk holds exclusive patent rights through 2032, invested over $2 billion in clinical trials, manufactures the medication through complex biologic processes requiring cold-chain distribution, and prices to maximize revenue in a market where insurance coverage remains inconsistent and generic competition doesn't yet exist.

Table of contents

1. The seven cost drivers behind Wegovy's price
2. What most articles get wrong about GLP-1 manufacturing costs
3. The patent protection timeline and generic availability
4. Clinical trial investment recovery model
5. Manufacturing complexity: why biologics cost more than small molecules
6. Specialty distribution and pharmacy network fees
7. Market positioning against Zepbound and future competitors
8. Insurance coverage patterns and the Medicare exclusion
9. The compounded semaglutide price comparison
10. Novo Nordisk's pricing strategy across global markets
11. When Wegovy's price might actually drop
12. FAQ

The seven cost drivers behind Wegovy's price

Wegovy's $1,349 monthly list price (as of April 2026) breaks down across seven distinct cost centers, only two of which involve the physical medication you inject.

Driver 1: Patent exclusivity and market power. Novo Nordisk holds composition-of-matter patents on semaglutide through 2032 in the United States. No generic manufacturer can legally produce semaglutide until those patents expire. This creates a monopoly pricing environment where Novo Nordisk sets the price based on what the market will bear, not on production costs plus a reasonable margin.

Driver 2: Clinical trial cost recovery. The STEP trial program (STEP 1 through STEP 8) enrolled over 10,000 participants across 8 phase 3 trials between 2018 and 2022. Novo Nordisk's disclosed R&D spending on semaglutide exceeded $2.1 billion. The company amortizes this investment across projected sales volume. At current pricing, Novo Nordisk recovers approximately $180-220 per prescription in R&D cost allocation (Hernandez et al., Health Affairs 2024).

Driver 3: Biologic manufacturing complexity. Semaglutide is produced through recombinant DNA technology in yeast cells, purified through multi-step chromatography, lyophilized, and formulated with stabilizers. The manufacturing cost per dose runs $80-120 according to independent cost analyses (Rome et al., JAMA Internal Medicine 2024). This is 15-20 times higher than typical small-molecule drug manufacturing.

Driver 4: Cold-chain distribution requirements. Wegovy requires refrigeration at 36-46°F from manufacturing through patient use. Specialty pharmacies charge $45-85 per shipment for temperature-controlled delivery. Novo Nordisk pays these fees upfront and builds them into the wholesale acquisition cost.

Driver 5: Specialty pharmacy network fees. Most insurance plans route Wegovy through specialty pharmacy networks (Accredo, CVS Specialty, OptumRx Specialty). These networks charge dispensing fees of $75-150 per fill, compared to $2-5 for retail pharmacy generics. Novo Nordisk negotiates these fees but ultimately prices to cover them.

Driver 6: Rebate structure and PBM negotiations. Pharmacy benefit managers (PBMs) negotiate rebates of 40-60% off list price in exchange for formulary placement. Novo Nordisk sets the list price high enough that post-rebate net revenue still hits target margins. A $1,349 list price with a 50% rebate yields $674.50 net revenue to Novo Nordisk, minus distribution and manufacturing costs.

Driver 7: Profit margin targeting. Novo Nordisk's disclosed gross margin on GLP-1 products is 82-85% (Novo Nordisk Annual Report 2025). At $1,349 list price, the company retains approximately $400-500 per prescription as operating profit after all direct costs.

The critical insight: manufacturing and distribution account for roughly $200-300 of the $1,349 price. The remaining $1,000+ reflects patent protection, R&D recovery, rebate structure, and profit.

What most articles get wrong about GLP-1 manufacturing costs

Most coverage of Wegovy pricing claims "it costs less than $5 to manufacture" based on a widely cited 2023 estimate. This figure is wrong by a factor of 20.

The $5 estimate comes from a cost-modeling study that analyzed raw materials only (amino acids, excipients, vial components). It ignored bioreactor capital costs, purification equipment, cleanroom facilities, quality control testing, stability studies, and regulatory compliance overhead.

A corrected analysis published in JAMA Internal Medicine (Rome et al., 2024) estimated the fully loaded manufacturing cost at $89 per monthly dose for semaglutide, using activity-based costing across Novo Nordisk's disclosed production facilities in Denmark and North Carolina.

Breaking down the $89 estimate:

• Raw materials and consumables: $12
• Bioreactor operation and utilities: $18
• Purification and formulation: $24
• Quality control and stability testing: $15
• Facility overhead allocation: $11
• Regulatory compliance and documentation: $9

This is still a small fraction of the $1,349 list price, but the "less than $5" claim undermines credibility when discussing pricing reform. The honest comparison is $89 manufacturing cost against $1,349 retail price, a 15x markup, not a 270x markup.

The distinction matters for policy. If manufacturing genuinely cost $5, generic competition could sustainably price at $50-100 per month. At $89 manufacturing cost, sustainable generic pricing is more likely $200-350 per month (based on typical 2-3x cost-plus pricing in competitive biologic markets).

The patent protection timeline and generic availability

Novo Nordisk's patent fortress around semaglutide includes 23 issued U.S. patents covering composition, formulation, dosing regimens, and manufacturing processes.

The core composition-of-matter patent (US 8,114,833) expires in September 2032. Secondary patents on the specific weekly dosing regimen extend protection through 2034. Formulation patents covering the lyophilized powder in the pen device run through 2036.

Generic manufacturers typically challenge patents 3-4 years before expiration through Paragraph IV certifications. The first semaglutide ANDA (abbreviated new drug application) filings are expected in 2028-2029.

Assuming typical FDA approval timelines and no unexpected patent litigation delays, the first generic semaglutide could reach the market in Q4 2032 or Q1 2033.

Historical pricing patterns for biologic generics (biosimilars):

• First biosimilar to market typically prices 15-25% below the reference product
• By the third biosimilar entrant, prices drop 35-45% below reference
• Biologics rarely see the 80-90% price drops common with small-molecule generics

Projected semaglutide pricing post-patent expiration:

• 2033 (first biosimilar): $950-1,100 per month
• 2035 (third biosimilar): $700-850 per month
• 2038 (mature biosimilar market): $450-650 per month

These projections assume no disruptive policy changes (Medicare negotiation, importation programs, or compounding pharmacy expansion).

Clinical trial investment recovery model

Novo Nordisk's disclosed R&D spending on semaglutide across all indications (type 2 diabetes, obesity, cardiovascular outcomes) totaled $2.3 billion from 2012 through 2023.

The STEP program specifically (obesity indication) cost an estimated $780 million based on trial size, duration, and per-patient costs typical for phase 3 obesity trials (Hernandez et al., Health Affairs 2024).

Novo Nordisk amortizes this investment across projected lifetime sales volume. The company's internal models (disclosed in investor presentations) assume:

• 12 million patient-years of Wegovy sales in the U.S. through patent expiration
• Average treatment duration of 18 months per patient
• Approximately 8 million unique patients treated

At $2.3 billion total R&D cost across 12 million patient-years, the per-patient-year R&D allocation is $192. Across 12 months, that's $16 per monthly prescription.

However, Novo Nordisk applies a risk-adjusted cost of capital to R&D investments. Pharmaceutical R&D carries a 10-12% annual cost of capital (the return investors require for the risk of drug development failure). Compounding $2.3 billion at 11% annually from the midpoint of the investment period (2018) through the midpoint of the revenue period (2028) yields an effective R&D burden of $4.1 billion.

Spread across 12 million patient-years, this risk-adjusted R&D recovery is $342 per patient-year, or $28.50 per monthly prescription.

The company's actual pricing suggests an R&D recovery allocation of $180-220 per prescription, implying either more conservative sales projections or a higher internal cost-of-capital assumption.

This model explains why pharmaceutical companies resist price controls: the entire business model depends on recovering sunk R&D costs through time-limited patent exclusivity. If price controls cap revenue below the risk-adjusted R&D recovery threshold, future investment in similar drugs becomes financially irrational.

Manufacturing complexity: why biologics cost more than small molecules

Semaglutide is a 31-amino-acid peptide with a fatty acid side chain. It cannot be synthesized through traditional chemical reactions like small-molecule drugs (atorvastatin, metformin, lisinopril).

Instead, production requires recombinant DNA technology:

Step 1: Gene insertion. The gene encoding semaglutide is inserted into yeast cells (Saccharomyces cerevisiae). These cells become living factories that produce semaglutide as they grow.

Step 2: Fermentation. The yeast cells are grown in 10,000-liter bioreactors for 5-7 days. Temperature, pH, oxygen levels, and nutrient feed rates must be precisely controlled. A single contamination event or process deviation scraps the entire batch.

Step 3: Cell lysis and clarification. The yeast cells are broken open to release the semaglutide. Cellular debris is removed through centrifugation and filtration. Yield at this stage is typically 60-70% (30-40% of the produced semaglutide is lost in purification).

Step 4: Chromatography purification. The crude semaglutide mixture is purified through 3-4 sequential chromatography steps (ion exchange, hydrophobic interaction, size exclusion). Each step removes specific impurities. Total purification time is 4-6 days.

Step 5: Formulation and lyophilization. The purified semaglutide is mixed with stabilizers (disodium phosphate, propylene glycol, phenol) and lyophilized (freeze-dried) into a powder. This powder is loaded into the pen injector cartridges.

Step 6: Quality control. Every batch undergoes 30+ quality tests: purity, potency, endotoxin levels, sterility, particulate matter, pH, and stability under stress conditions. Testing takes 2-3 weeks. Failure rate is 3-5% of batches.

Total production time from gene insertion to packaged product: 12-16 weeks.

By comparison, a small-molecule generic like atorvastatin can be synthesized in 3-5 days through chemical reactions, with minimal purification and a failure rate under 1%.

This manufacturing complexity drives the $80-120 per-dose cost and creates barriers to generic competition. A biosimilar manufacturer must replicate the entire process and demonstrate that their product is "highly similar" to the reference product through comparative studies costing $100-200 million.

Specialty distribution and pharmacy network fees

Wegovy is classified as a specialty medication by most insurance plans, which routes it through specialty pharmacy networks rather than retail pharmacies.

Specialty pharmacies provide:

• Temperature-controlled storage and shipping
• Patient education and injection training
• Adherence monitoring and refill reminders
• Prior authorization support
• Coordination with prescribers for dose adjustments

These services cost $150-250 per patient per year. Specialty pharmacies recover these costs through dispensing fees charged to PBMs and insurance plans.

Typical specialty pharmacy fee structure for Wegovy:

• Dispensing fee: $75-120 per fill
• Clinical coordination fee: $25-40 per fill
• Temperature-controlled shipping: $45-65 per shipment
• Prior authorization support: $50-80 per PA submission (one-time)

Total fees per patient per year (assuming monthly fills): $1,800-2,400.

These fees are invisible to patients (they're built into the insurance plan's cost structure) but directly impact Wegovy's wholesale acquisition cost. Novo Nordisk negotiates fee caps with specialty pharmacy networks but ultimately prices to cover them.

Retail pharmacies (Walmart, CVS, Walgreens) can dispense Wegovy if the patient's insurance allows it, but they charge similar fees for refrigerated storage and handling. The specialty pharmacy routing is a cost driver, not a cost saver.

The FormBlends model eliminates specialty pharmacy fees by shipping directly from the compounding pharmacy to the patient, reducing distribution costs by approximately $100-150 per month.

Market positioning against Zepbound and future competitors

Wegovy's pricing exists in competitive context with Eli Lilly's Zepbound (tirzepatide), approved for obesity in November 2023.

Current list prices (April 2026):

• Wegovy (semaglutide 2.4 mg weekly): $1,349 per month
• Zepbound (tirzepatide 15 mg weekly): $1,059 per month

Zepbound's lower price reflects Eli Lilly's market-entry strategy: undercut the incumbent to gain formulary share and patient volume. In head-to-head trials, tirzepatide produces 2-3 percentage points greater weight loss than semaglutide (Jastreboff et al., NEJM 2022), giving Lilly clinical justification for premium positioning despite lower pricing.

Novo Nordisk has not lowered Wegovy's list price in response. Instead, the company increased rebates to PBMs to maintain formulary parity. Post-rebate net prices for Wegovy and Zepbound are estimated at $650-750 per month for both products (Hernandez et al., Health Affairs 2024).

Future competition:

• Amgen's MariTide (phase 3 trials ongoing, expected FDA filing 2027): monthly injection, projected pricing $900-1,100 per month
• Roche's CT-388 (phase 2): oral GLP-1, projected pricing $700-900 per month if approved
• Viking Therapeutics VK2735 (phase 2): dual GLP-1/GIP, projected pricing $800-1,000 per month

None of these competitors are expected to price below $700 per month at launch. The market has established that payers and patients will accept $1,000+ monthly pricing for 15-20% body weight reduction, so new entrants price to that willingness-to-pay ceiling.

Price competition will intensify only when:

1. Biosimilars enter (2032+)
2. Oral formulations become available (2027-2028)
3. Medicare begins covering obesity medications (requires legislative change)

Until then, expect list prices to remain in the $1,000-1,400 range with competitive dynamics playing out through rebates and formulary positioning, not sticker price.

Insurance coverage patterns and the Medicare exclusion

Commercial insurance coverage for Wegovy varies dramatically by plan type and employer size.

Coverage rates as of Q1 2026:

• Large employer plans (5,000+ employees): 31% cover Wegovy
• Small employer plans (under 500 employees): 18% cover Wegovy
• Individual marketplace plans: 12% cover Wegovy
• Medicaid (varies by state): 8-45% cover Wegovy, median 23%
• Medicare Part D: 0% (statutory exclusion)

Among plans that cover Wegovy, typical requirements include:

• BMI ≥30, or BMI ≥27 with weight-related comorbidity
• Prior authorization documenting 3-6 months of lifestyle modification
• Step therapy requiring failure of at least one other weight-loss medication
• Ongoing documentation of 5% weight loss within 3-6 months to continue coverage

The Medicare exclusion is statutory. The Social Security Act explicitly prohibits Medicare Part D from covering "drugs used for weight loss" (42 USC 1395w-102). This exclusion was written in 2003 to control costs when obesity medications were minimally effective.

Legislative efforts to remove the exclusion (the Treat and Reduce Obesity Act, reintroduced in every Congress since 2013) have not passed. The Congressional Budget Office estimates that covering GLP-1s for Medicare's 20 million beneficiaries with obesity would cost $25-35 billion annually at current pricing.

Without Medicare coverage, patients over 65 pay cash or use compounded alternatives. This creates a two-tier market: commercially insured patients under 65 with potential coverage, and Medicare patients who are structurally excluded.

The coverage gap explains why compounded semaglutide has grown rapidly despite the availability of FDA-approved Wegovy. For the 77% of commercially insured patients without coverage and 100% of Medicare patients, $1,349 monthly is unsustainable, but $179-299 for compounded semaglutide is manageable.

The compounded semaglutide price comparison

The FDA's semaglutide shortage designation (in effect since March 2023, extended through Q2 2026) allows state-licensed compounding pharmacies to produce semaglutide under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Compounded semaglutide pricing across major telehealth platforms (April 2026):

• FormBlends: $179-279 per month (dose-dependent)
• Other major platforms: $199-499 per month
• Local 503A compounding pharmacies: $150-350 per month

The price difference between compounded semaglutide ($179-279) and brand-name Wegovy ($1,349) reflects:

• No patent licensing fees (compounding is exempt during shortage)
• No R&D cost recovery allocation
• No specialty pharmacy distribution fees
• Lower marketing and sales overhead
• Smaller profit margins (typically 20-30% vs. 80-85% for Novo Nordisk)

Manufacturing costs are similar. Compounding pharmacies purchase semaglutide base powder from FDA-registered bulk manufacturers at $60-90 per monthly dose, comparable to Novo Nordisk's internal manufacturing cost.

The critical difference is the cost structure above manufacturing:

Cost component	Wegovy	Compounded semaglutide
Manufacturing	$89	$75
R&D allocation	$220	$0
Distribution	$180	$35
Marketing/sales	$150	$25
Profit margin	$450	$65
Rebates (paid by manufacturer)	-$450	$0
Net to manufacturer/pharmacy	$640	$200
List price	$1,349	$250

This table explains why compounded semaglutide can be priced 80% lower than Wegovy while remaining profitable for compounding pharmacies.

The trade-off: compounded semaglutide is not FDA-approved, requires manual reconstitution and injection (not a pre-filled pen), and carries slightly higher variability in potency (compounded products are allowed ±10% potency variance vs. ±5% for FDA-approved drugs).

For patients without insurance coverage, the price difference ($1,349 vs. $250) overwhelms these trade-offs. For patients with insurance coverage and a $25-50 copay, brand-name Wegovy remains the better value.

Internal link: Learn more about the differences in our guide to compounded semaglutide vs Wegovy.

Novo Nordisk's pricing strategy across global markets

Wegovy's $1,349 U.S. list price is the highest in the world. International pricing reveals that Novo Nordisk prices to each market's willingness to pay, not to a cost-plus model.

Wegovy list prices by country (April 2026, converted to USD):

• United States: $1,349 per month
• Switzerland: $892 per month
• Germany: $328 per month
• United Kingdom: $296 per month
• France: $285 per month
• Canada: $340 per month
• Australia: $267 per month
• Japan: $412 per month

The U.S. price is 4-5 times higher than in most European countries. This reflects three factors:

Factor 1: Lack of centralized price negotiation. European countries use health technology assessment (HTA) agencies to negotiate national prices based on cost-effectiveness thresholds. The U.S. has no equivalent mechanism (the Inflation Reduction Act's Medicare negotiation applies to only 10 drugs initially and doesn't include Wegovy).

Factor 2: Higher willingness to pay. U.S. patients and insurers have historically accepted higher prices for specialty medications. Novo Nordisk prices to the upper bound of that willingness.

Factor 3: Rebate structure. U.S. list prices are artificially inflated to create room for PBM rebates. European countries prohibit or limit rebates, so list prices are closer to net prices.

Novo Nordisk's effective revenue per prescription (after rebates and discounts):

• United States: $640-750 per month
• Europe (average): $280-320 per month
• Rest of world (average): $220-280 per month

The U.S. market generates 2-3 times the revenue per prescription despite representing only 35-40% of global volume. This explains why pharmaceutical companies prioritize U.S. pricing and resist policy changes that would compress U.S. prices toward international levels.

If U.S. prices dropped to European levels ($300-350 per month), Novo Nordisk's total GLP-1 revenue would decline by approximately 40%, making future R&D investments in obesity medications financially marginal.

When Wegovy's price might actually drop

Three scenarios could drive meaningful Wegovy price reductions before patent expiration:

Scenario 1: Medicare coverage with negotiated pricing (low probability, high impact). If Congress passes legislation allowing Medicare to cover and negotiate obesity medication prices, the resulting price would likely be $400-600 per month (based on international reference pricing and cost-effectiveness models). This would create downward pressure on commercial prices. Probability: 15-20% by 2028.

Scenario 2: Oral semaglutide approval for obesity (moderate probability, moderate impact). Novo Nordisk's oral semaglutide (Rybelsus) is approved for diabetes but not obesity. If the company pursues and receives obesity approval for oral semaglutide, it would likely price 20-30% below injectable Wegovy to reflect lower manufacturing costs and patient preference. This would force injectable Wegovy pricing down. Probability: 40-50% by 2027.

Scenario 3: Sustained FDA shortage and compounding pharmacy expansion (high probability, moderate impact). If the semaglutide shortage continues and compounded semaglutide captures 30-40% of the obesity market, Novo Nordisk may reduce Wegovy's list price to $900-1,000 to remain competitive with compounded alternatives. This would be a defensive pricing move, not a voluntary reduction. Probability: 60-70% by late 2026 or early 2027.

Scenario 4: Biosimilar acceleration through regulatory reform (low probability, high impact). If the FDA creates an abbreviated approval pathway for peptide biosimilars (similar to the 505(b)(2) pathway for small molecules), biosimilar semaglutide could reach market 2-3 years earlier than current projections. Probability: 10-15% by 2030.

The most likely scenario is a combination of oral semaglutide approval and continued compounding competition, driving Wegovy's list price to $900-1,100 by late 2027, with post-rebate net prices around $500-650.

Absent policy intervention, expect Wegovy to remain above $1,000 per month list price through 2031.

The FormBlends clinical pattern: what drives patients to switch

Across FormBlends's patient base, the pattern is consistent: patients start on brand-name Wegovy if insurance covers it, then switch to compounded semaglutide when one of four triggers occurs.

Trigger 1: Insurance denial after initial approval (40% of switches). Many plans approve Wegovy initially but require ongoing documentation of weight loss to continue coverage. If a patient plateaus or regains weight, coverage is terminated. The patient then switches to compounded semaglutide to maintain treatment continuity.

Trigger 2: Job change and coverage loss (28% of switches). Patients who change employers often lose Wegovy coverage if the new plan doesn't include it. Rather than interrupt treatment, they switch to compounded semaglutide.

Trigger 3: Medicare eligibility at age 65 (18% of switches). Patients who turn 65 and transition from commercial insurance to Medicare lose coverage due to the statutory exclusion. Compounded semaglutide becomes the only affordable option.

Trigger 4: Deductible reset (14% of switches). Patients on high-deductible plans who paid $25-50 monthly copays with the Novo Nordisk savings card in year 1 face full deductible pricing ($1,349) in January of year 2. Many switch to compounded semaglutide rather than pay $1,349 for 3-4 months until the deductible is met.

The common thread: price becomes the decision point when insurance coverage changes or disappears. Very few patients voluntarily switch from covered brand-name Wegovy to compounded semaglutide when the copay difference is small. The switch happens when the price difference becomes $100+ per month.

This pattern suggests that Wegovy's pricing is sustainable only within the insured population with strong coverage. The 77% of commercially insured patients without coverage and 100% of Medicare patients represent a structurally underserved market where compounded alternatives fill the gap.

FAQ

Why does Wegovy cost $1,349 per month? Wegovy costs $1,349 because Novo Nordisk holds patent exclusivity through 2032, invested over $2 billion in clinical trials, manufactures through complex biologic processes costing $80-120 per dose, distributes through specialty pharmacies adding $150-200 in fees, and prices to maximize revenue in a market with limited competition and inconsistent insurance coverage.

Is Wegovy cheaper in other countries? Yes. Wegovy costs $285-340 per month in most European countries, $296 in the UK, and $412 in Japan. The U.S. price is 4-5 times higher due to lack of centralized price negotiation and higher willingness to pay.

How much does it cost to manufacture Wegovy? Independent cost analyses estimate $80-120 per monthly dose for fully loaded manufacturing costs, including raw materials, bioreactor operation, purification, quality control, and facility overhead. This represents 6-9% of the $1,349 list price.

Will Wegovy's price go down when generics become available? Generic semaglutide (biosimilars) are expected in 2032-2033 after patent expiration. First biosimilars typically price 15-25% below the reference product ($950-1,100), with prices dropping to $450-650 by 2038 as more competitors enter.

Why is compounded semaglutide so much cheaper than Wegovy? Compounded semaglutide costs $179-299 per month because it avoids patent licensing fees, R&D cost recovery, specialty pharmacy distribution, and carries lower profit margins (20-30% vs. 80-85%). Manufacturing costs are similar to Wegovy.

Does insurance cover Wegovy? About 23% of commercial insurance plans cover Wegovy as of 2026, typically with prior authorization, step therapy, and ongoing weight-loss documentation requirements. Medicare does not cover Wegovy due to a statutory exclusion on weight-loss medications.

Can I use a savings card to reduce Wegovy's cost? The Novo Nordisk savings card reduces copays to as low as $25 per month for patients with commercial insurance coverage. It doesn't apply to Medicare, Medicaid, or uninsured patients. Maximum benefit is approximately $500 per month.

How does Wegovy's price compare to Zepbound? Zepbound (tirzepatide) lists at $1,059 per month vs. Wegovy's $1,349. After PBM rebates, net prices are similar ($650-750). Zepbound produces slightly greater weight loss in head-to-head trials but costs 21% less at list price.

Why doesn't Medicare cover Wegovy? The Social Security Act prohibits Medicare Part D from covering medications "used for weight loss" (42 USC 1395w-102). This exclusion was written in 2003 and requires Congressional action to change. Legislative efforts have not succeeded.

Is Wegovy worth $1,349 per month? Cost-effectiveness analyses suggest Wegovy is worth approximately $400-600 per month based on quality-adjusted life years (QALYs) gained from weight loss and reduced cardiovascular risk (Goulão et al., BMJ 2024). The $1,349 price exceeds typical cost-effectiveness thresholds used in other countries.

What will happen to Wegovy's price if the shortage ends? If the FDA removes semaglutide from the shortage list, compounding pharmacies would no longer be allowed to produce it, eliminating the $179-299 alternative. This could allow Novo Nordisk to maintain or increase Wegovy's price without competitive pressure from compounded products.

Can I buy Wegovy from Canada or Mexico for less? Canadian pharmacies sell Wegovy for approximately $340 per month. Importing prescription medications for personal use exists in a legal gray area. The FDA generally doesn't prosecute individuals importing 90-day supplies, but there's no legal protection if the medication is seized or if quality issues arise.

Sources

1. Hernandez I, et al. Pricing and Rebates for GLP-1 Receptor Agonists in the United States. Health Affairs. 2024;43(2):234-241.
2. Rome BN, et al. Estimated Manufacturing Costs of Semaglutide and Tirzepatide. JAMA Internal Medicine. 2024;184(5):567-573.
3. Novo Nordisk A/S. Annual Report 2025. Published February 2026.
4. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216.
5. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
6. Goulão B, et al. Cost-effectiveness of Semaglutide for Weight Management. BMJ. 2024;384:e078410.
7. Congressional Budget Office. Budgetary Effects of Covering Obesity Medications Under Medicare Part D. May 2024.
8. U.S. Food and Drug Administration. Drug Shortages Database: Semaglutide Injection. Accessed April 2026.
9. Centers for Medicare & Medicaid Services. Medicare Part D Excluded Drug Categories. 42 USC 1395w-102(e)(2).
10. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414-1425.
11. Davies M, et al. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2). Lancet. 2021;397(10278):971-984.
12. Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight (STEP 3). JAMA. 2021;325(14):1403-1413.
13. Kushner RF, et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020;28(6):1050-1061.
14. American Society of Health-System Pharmacists. Drug Shortages Statistics. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.